CY1107750T1 - Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης - Google Patents

Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης

Info

Publication number
CY1107750T1
CY1107750T1 CY20071101262T CY071101262T CY1107750T1 CY 1107750 T1 CY1107750 T1 CY 1107750T1 CY 20071101262 T CY20071101262 T CY 20071101262T CY 071101262 T CY071101262 T CY 071101262T CY 1107750 T1 CY1107750 T1 CY 1107750T1
Authority
CY
Cyprus
Prior art keywords
release
controlled
ssri
formulation
polymosphatic
Prior art date
Application number
CY20071101262T
Other languages
English (en)
Inventor
Theresa Ann Jeary
Catherine Ann Morrissey
Paul Stark
Original Assignee
Elan Pharma International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE19990406A external-priority patent/IE990406A1/en
Application filed by Elan Pharma International Limited filed Critical Elan Pharma International Limited
Publication of CY1107750T1 publication Critical patent/CY1107750T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ένα πολυσωματιδιακό σκεύασμα ελεγχόμενης αποδέσμευσης εκλεκτικού αναστολέα επαναπρόσληψης σεροτονίνης (SSRI) για στοματική χορήγηση περιλαμβάνει σωματίδια του εν λόγω SSRI ή ενός φαρμακευτικώς αποδεκτού άλατος αυτού επικαλυμμένα με πολυμερές ελέγχου της ταχύτητας το οποίο καθιστά δυνατή την ελεγχόμενη αποδέσμευση του εν λόγω SSRI, μέσα σε μια περίοδο όχι μικρότερη από περίπου 12 ώρες μετά την στοματική χορήγηση. Το σκεύασμα, το οποίο περιέχει για παράδειγμα φλουβοξαμίνη ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, είναι κατάλληλο για καθημερινή χορήγηση μία φορά ή δύο φορές. Το σκεύασμα μπορεί να περιλαμβάνει ένα μείγμα δύο ή περισσότερων πληθυσμών σωματιδίων, πελετών ή μικρο-δισκίων που έχουν διαφορετικά in vitro και/ή in vivo χαρακτηριστικά αποδέσμευσης.
CY20071101262T 1999-05-20 2007-10-04 Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης CY1107750T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13502899P 1999-05-20 1999-05-20
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP00925548A EP1178780B1 (en) 1999-05-20 2000-05-10 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Publications (1)

Publication Number Publication Date
CY1107750T1 true CY1107750T1 (el) 2013-04-18

Family

ID=26320248

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101262T CY1107750T1 (el) 1999-05-20 2007-10-04 Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης

Country Status (16)

Country Link
EP (2) EP1852111A1 (el)
JP (1) JP2003500348A (el)
AT (1) ATE367153T1 (el)
AU (1) AU782059B2 (el)
CA (2) CA2698347A1 (el)
CY (1) CY1107750T1 (el)
CZ (1) CZ302388B6 (el)
DE (1) DE60035579T2 (el)
DK (1) DK1178780T3 (el)
DZ (1) DZ3256A1 (el)
ES (1) ES2290027T3 (el)
HU (1) HU229569B1 (el)
PT (1) PT1178780E (el)
RU (1) RU2275191C2 (el)
SK (1) SK286865B6 (el)
WO (1) WO2000071099A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
RU2311903C2 (ru) * 2001-11-07 2007-12-10 Синтон Б.В. Таблетки тамзулосина
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
PT1502587E (pt) 2003-07-30 2007-01-31 Pharmathen Sa Formulação de libertação prolongada para cloridrato de venlafaxina
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
JP2008231025A (ja) * 2007-03-20 2008-10-02 Kyowa Yakuhin Kogyo Kk マレイン酸フルボキサミン錠剤
WO2018206923A1 (en) * 2017-05-11 2018-11-15 Opal Ip Limited Novel formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
AU739261B2 (en) * 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
UA63953C2 (uk) * 1997-07-01 2004-02-16 Пфайзер Продактс Інк. Дозована форма уповільненого вивільнення, що містить сертралін, (варіанти) та спосіб лікування (варіанти)
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation

Also Published As

Publication number Publication date
AU782059B2 (en) 2005-06-30
RU2275191C2 (ru) 2006-04-27
DE60035579D1 (de) 2007-08-30
CA2698347A1 (en) 2000-11-30
WO2000071099A1 (en) 2000-11-30
JP2003500348A (ja) 2003-01-07
HUP0201884A3 (en) 2006-07-28
SK286865B6 (sk) 2009-06-05
AU4426700A (en) 2000-12-12
SK18962001A3 (sk) 2002-04-04
DZ3256A1 (fr) 2000-11-30
EP1852111A1 (en) 2007-11-07
CZ302388B6 (cs) 2011-04-27
CA2374039C (en) 2011-01-11
DK1178780T3 (da) 2007-11-12
ES2290027T3 (es) 2008-02-16
CZ20014618A3 (cs) 2002-05-15
EP1178780B1 (en) 2007-07-18
CA2374039A1 (en) 2000-11-30
DE60035579T2 (de) 2008-04-17
EP1178780A1 (en) 2002-02-13
HUP0201884A2 (en) 2002-09-28
ATE367153T1 (de) 2007-08-15
PT1178780E (pt) 2007-10-25
HU229569B1 (hu) 2014-02-28

Similar Documents

Publication Publication Date Title
CY1107750T1 (el) Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης
RS50924B (sr) Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije
AR042472A1 (es) Preparaciones de liberacion controlada que comprenden tramadol y topiramato
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
PE20030527A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
IT1311923B1 (it) Composti farmaceutici.
SE9904505D0 (sv) Novel compounds
SV1999000194A (es) Preparado farmaceuticio de moxifloxacina ref. lea 33327-sv
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
FR2677886B1 (fr) Comprime matriciel permettant la liberation prolongee d&#39;indapamide apres administration par voie orale.
NO985964D0 (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
HUP0003413A2 (hu) Új kondenzált piridinszármazékok, eljárás előállításukra és az azokat tartalmazó gyógyászati készítmények
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
BR9915111A (pt) Partìculas revestidas de ibuprofeno cristalinogranulado
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
EA200300110A1 (ru) Композиция элетриптана в виде частиц
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
AR005008A1 (es) Compuestos benzotiazolona etanaminas, procedimiento e intermediarios para su preparacion y su uso en la preparacion de medicamentos
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase